173 related articles for article (PubMed ID: 8392903)
1. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
[TBL] [Abstract][Full Text] [Related]
2. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
6. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
[TBL] [Abstract][Full Text] [Related]
7. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
Kostić D; Jelić S; Radulović S
Srp Arh Celok Lek; 2000; 128(3-4):75-9. PubMed ID: 10932613
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Gridelli C; D'Aprile M; Palmeri S; Curcio C; Rossi A; Gebbia V; Veltri E; Pepe R; Pistillucci G; Bianco AR
Am J Clin Oncol; 1996 Dec; 19(6):589-91. PubMed ID: 8931678
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
[TBL] [Abstract][Full Text] [Related]
10. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
[TBL] [Abstract][Full Text] [Related]
12. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
14. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
Rosell R; Gómez-Codina J; Anton A; Sánchez JJ; Vadell C
Semin Oncol; 1994 Feb; 21(1 Suppl 1):48-53. PubMed ID: 8153657
[No Abstract] [Full Text] [Related]
15. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
[TBL] [Abstract][Full Text] [Related]
18. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
Riccardi A; Danova M; Paccagnella A; Giordano M; Favaretto A; Panozzo M; Ghiotto C; Comis S; Fiorentino M; Chieco-Bianchi L
Ann Hematol; 1993 Apr; 66(4):185-93. PubMed ID: 8387346
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]